Tempus AI, a technology company focused on advancing precision medicine using artificial intelligence (AI), has announced a strategic collaboration with the advocacy organization Blood Cancer United to develop a comprehensive, patient-centered registry for children with a rare blood cancer.
The registry, which includes tools for patients and researchers, will focus on pediatric acute myeloid leukemia (pAML), a rare and aggressive form of the disease.
Registry will provide tools and data for patients and researchers
“This collaboration will help patients and families now and lays the groundwork for an innovative, patient‑centered approach for the future,” Gwen Nichols, MD, chief medical officer at Blood Cancer United (formerly The Leukemia & Lymphoma Society), said in a press release.
Patients who join the registry will get access to Tempus’ health app olivia, an AI-enabled personal health concierge that provides tailored information using clinical data and resources from Blood Cancer United. The app will enable the collection of longitudinal patient-reported outcomes and questionnaire data to contribute to the registry.
“By combining Tempus’ AI-enabled platform with Blood Cancer United’s deep connection to the patient community, we can create a powerful resource that we hope will improve both care and outcomes for children diagnosed with this devastating disease,” said Max Banaszak, chief operating officer of data & apps at Tempus.
In addition to providing services to patients, de-identified data collected through the registry will be made available to researchers through Tempus’ cloud-based analytics platform, Lens. This platform enables scientists to access and analyze multimodal, de-identified data from the registry, with the aim of supporting research and generating new insights into this rare cancer.
Registry data may help inform clinical trials in rare cancers
“For rare disease subtypes like pediatric leukemia, it can be a challenge to enroll enough patients for both an experimental arm and a traditional control arm, which can delay or even prevent trials from starting,” Nichols said. “Our vision is to combine patient‑reported outcomes with de‑identified medical and genomic data to create external control arms and other real‑world comparators, which will allow trials to run faster, let more children receive investigational therapies, and bring safer, more effective treatments to kids sooner.”
The new partnership is part of Blood Cancer United’s Dare to Dream Project, a $175 million capital campaign aimed at improving care for children with blood cancers.
“Our work with the Blood Cancer United Dare to Dream Project is a significant step forward in our shared commitment to advance precision medicine, particularly in rare cancers like pediatric AML where high-quality, comprehensive data is desperately needed,” Banaszak said.
The post New registry aims to support research for pediatric acute myeloid leukemia appeared first on Rare Cancer News.